Hospital

In a clinical trial, tenecteplase was shown to be a comparable alternative to alteplase.

The decisions were made amid the United States worst flu outbreak in over 2 decades.

The data were released in the CDC’s Morbidity and Mortality Weekly Report.

Tuberculosis is a long-standing global health issue that requires continued public health vigilance to prevent a resurgence of this preventable and curable disease.

Trastuzumab rezetecan is a novel antibody-drug conjugate.

The advanced therapy yielded superior enhanced mucus secretion compared with available therapies.

The results act as a contradiction to conventional wisdom of high-density lipoprotein (HDL) cholesterol being healthy and lowering the risk of heart disease, but more research is warranted.

RSV infection resulted in higher costs among specific age groups, especially patients aged 70 to 80 years.

Patients achieved an overall survival of 12.4 months.

If approved, gepotidacin (GSK) will be a new oral agent added to the treatment paradigm for urinary tract infections (UTIs).

Pharmacists play a crucial role in understanding and responding to these developments, ensuring patients remain informed about the latest advancements and potential threats.

Glecirasib is a potent oral inhibitor of KRASG12C.

Sacituzumab govitecan improves outcomes but requires careful management of adverse effects.

Officials urge vaccinations as mobile vaccine drives ramp up to contain the outbreak.

Even for patients with myelofibrosis who could otherwise proceed directly to hematopoietic cell transplantation, pre-transplant treatment with ruxolitinib led to improved survival benefits.

Pharmacists must consider drug Interactions, allergies, and comorbidities when treating patients with urinary tract infections (UTIs).

Fred Saad, MD, discussed findings from the phase 3 ARANOTE and ARASENS trials.

Risk stratification remains a challenge when selecting patients for treatment of smoldering multiple myeloma.

Clinical pharmacists can optimize treatment through effective medication management and therapeutic drug monitoring.

New options for tirzepatide provide a transparent, out-of-pocket choice for patients by streamlining the supply chain and bypassing insurance.

Although tenofovir amibufenamide and tenofovir disoproxil fumarate (TDF) had similar effects, the former resulted in better renal safety and did not impact lipid levels.

Research has demonstrated a reduction in hospitalization risk associated with the use of LAIs, but some barriers can prevent the wider adoption of this approach.

Pembrolizumab is a humanized monoclonal antibody that targets PD-1.

The authors note that this lack of inclusion can leave important safety and efficacy questions unanswered.

Gaps in education about biosimilars, particularly among pharmacists, patients, and prescribers, are a significant barrier to wider adoption.

Tanshinlactone is an active ingredient that is commonly used in Chinese herbal medicine.

The long-term durability of response will be evaluated in the B-Sure trial (NCT04954859), which will enroll patients with hepatitis B virus (HBV) from B-Together (NCT04676724).

Curbing RSV and its complications can reduce health care costs associated with its treatment.